Pattern Of Use Of Belatacept In US Transplant Recipients

Trial Profile

Pattern Of Use Of Belatacept In US Transplant Recipients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Belatacept (Primary) ; Calcineurin inhibitors
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Aug 2017 Planned End Date changed from 30 Jun 2017 to 30 Jun 2018.
    • 07 Aug 2017 Planned primary completion date changed from 30 Jun 2017 to 30 Jun 2018.
    • 04 Aug 2014 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top